GlassScriptPhysician profile
Jenifer Cotter
NPI 1750636270
$5,631.55
in general payments reported to CMS, 2019-2025
29 companies · $801 in 2025
The $801 reported for 2025 was more than what 94% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,070 · 2022: $1,247 · 2023: $1,358 · 2024: $1,156 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,298 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,298.12 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,626.71 | 2021-2025 | |
| Novo Nordisk INC | $765.17 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $635.63 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Pfizer INC. | $367.62 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.57 | 2021-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $270.52 | 2021-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $217.46 | 2021-2022 | |
| Exeltis, USA INC. | $195.29 | 2021-2025 | Slynd |
| Biohaven Pharmaceuticals, INC. | $155.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $139.77 | 2022 | |
| Mayne Pharma Commercial LLC | $101.45 | 2021-2025 | |
| Organon LLC | $101.25 | 2021-2024 | |
| Amgen INC. | $101.18 | 2021-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $89.97 | 2021-2024 | Tymlos |
| Sumitomo Pharma America, INC. | $85.28 | 2023-2025 | Myfembree, Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $70.14 | 2022 | |
| Ardelyx, INC. | $64.42 | 2024-2025 | Ibsrela |
| Millicent US INC | $62.77 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $45.93 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $45.01 | 2022-2023 | Vivjoa |
| Avion Pharmaceuticals | $42.31 | 2021-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $26.80 | 2025 | |
| Agile Therapeutics, INC. | $26.11 | 2021 | |
| Currax Pharmaceuticals LLC | $26.10 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $22.37 | 2021 | |
| Lupin INC. | $17.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.12 | 2021 | |
| Evofem Biosciences, INC. | $15.43 | 2021 | |
| Allergan, INC. | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenifer Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.